News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rexahn Pharmaceuticals, Inc. (RNN) Appoints Mark Carthy To Board Of Directors


3/3/2014 7:35:24 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the appointment of Mark P. Carthy to the company's Board of Directors.

"We are very pleased to have Mark join Rexahn’s Board of Directors," said Peter D. Suzdak, Ph.D., Rexahn’s Chief Executive Officer. "Mark’s extensive business and financing experience in the life sciences will be particularly important as we continue the development of our three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) for the treatment of multiple types of cancer.”

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES